A one-year hospital-based prospective CVOID-19 open-cohort in the Eastern Mediterranean region: The Khorshid COVID Cohort (KCC) study

Ramin Sami [1], Forogh Soltaninejad [2], Babak Amra [3], Zohreh Naderi [4], Shaghayegh Haghjooy Javanmard [5], Bijan Iraj [6], Somayeh Haji Ahmadi [7], Azin Shayganfar [8], Mehrnegar Dehghan [9], Nilufar Khademi [10], Nastaran Sadat Hosseini [11], Mojgan Mortazavi [12], Marjan Mansourian [13,14*], Miquel Angel Mañanas [15,16¶], Hamid Reza Marateb [17,18,19¶], Peyman Adibi [20†]

[1] Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

[2] The Respiratory Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

[3] Bamdad Respiratory Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

[4] Department of Pulmonology, University of Medical Science, Isfahan University, Isfahan, Iran

[5] Department of Physiology, School of Medicine, Applied Physiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

[6] Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

[7] Department of Radiology, Isfahan University of Medical Sciences, Isfahan, Iran

[8] Department of Radiology, Isfahan University of Medical Sciences, Isfahan, Iran

[9] School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

[10] School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

[11] School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

[12] Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

[13] Department of Epidemiology and Biostatistics, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran

[14] Biomedical Engineering Research Centre (CREB), Automatic Control Department (ESAII), Universitat Politècnica de Catalunya-Barcelona Tech (UPC), Barcelona, Spain

[15] Biomedical Engineering Research Centre (CREB), Automatic Control Department (ESAII), Universitat Politècnica de Catalunya-Barcelona Tech (UPC), Barcelona, Spain

[16] Biomedical Research Networking Center in Bioengineering, Biomaterials, and Nanomedicine (CIBER-BBN), Spain.

[17] Biomedical Engineering Department, Engineering Faculty, University of Isfahan, Isfahan, Iran

[18] Biomedical Engineering Research Centre (CREB), Automatic Control Department (ESAII), Universitat Politècnica de Catalunya-Barcelona Tech (UPC), Barcelona, Spain

[19] Machine Learning Department, Isfahan Cardiovascular Research Center (a WHO-collaborating center), Isfahan University of Medical Sciences, Isfahan, Iran

[20] Digestive Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

* Corresponding author

E-mail: marjan.mansourian@upc.edu (MM)

†These authors contributed equally to this work.

Abstract

The COVID-19 is rapidly scattering worldwide, and the number of cases in the Eastern Mediterranean Region is rising, there is a need for immediate targeted actions. We

designed a longitudinal study in a hot outbreak zone to analyze the serial findings between infected patients for detecting temporal changes from February 2020. In a hospital-based open-cohort study, patients are followed from admission until one year from their discharge (the 1st, 4th, 12th weeks, and the first year). The measurements included demographic, socio-economics, symptoms, health service diagnosis and treatment, contact history, and psychological variables. The signs improvement, death, length of stay in hospital were considered as primary, and impaired pulmonary function and psychotic disorders were considered as main secondary outcomes. Notably, In the last two follow-ups, each patient attends the hospital to complete the Patient Health Questionnaire-9 (PHQ-9) and the Depression Anxiety Stress Scales (DASS-21). Moreover, clinical symptoms and respiratory functions are being determined in such follow-ups. Among the first 600 COVID-19 cases, a total of 490 patients with complete information (39% female; the average age of 57±15 years) were analyzed. Seven percent of these patients died. The three main leading causes of admission were: fever (77%), dry cough (73%), and fatigue (69%). The most prevalent comorbidities between COVID-19 patients were hypertension (35%), diabetes (28%), and ischemic heart disease (14%). The percentage of primary composite endpoints (PCEP), defined as death, the use of mechanical ventilation, or admission to an intensive care unit was 18%. The following comorbidities were significantly different in the positive and negative PCEP groups: acute kidney disease (p=0.008) and diabetes (p=0.026). For signs and symptoms, fatigue (p=0.020) and sore throat (p=0.001) were significantly different. This long-term prospective Cohort may support healthcare professionals in the management of resources following this pandemic.

Introduction

The 2019 novel coronavirus disease (COVID-19) epidemic was officially announced by the World Health Organization (WHO) as an international public health emergency. Aggressive growth in the number of those affected with COVID-19 makes this virus such a threat. Patients were assessed for viral pneumonia through the ascertainment and testing of bronchoalveolar lavage fluid utilizing whole-genome sequencing, cell cultures, and polymerase chain reaction (PCR). In addition to a high rate of mortality, the disease has caused severe psychological problems among patients [1]. The clinical characteristics of COVID-19 patients were frequently reported [2]. Over 200 countries have a substantial incidence to date, including countries from the Middle East, North America, Asia, Australia, and Europe [3]. Currently, when COVID-19 is rapidly scattering worldwide, and the number of cases in the Middle East is rising with increasing pace in several affected areas, there is a need for immediate targeted action.

These high-risk procedures have implications for organization and medical practice of hospital care during this outbreak. Health policymakers everywhere plan for pandemics because their decisions can cause sharp shocks to societies and require a substantial, and massive change in health system capacity [4]. These problems, caused by the COVID-19, emphasizes the importance of analyzing the epidemiological data worthwhile. The COVID-19 studies have typically been focused on the initial clinical characteristics and the epidemiological description [5]. A majority of infected patients had mild to severe lung abnormalities on their chest CT scans when they were discharged from the hospital. Experts believe such groups may need closer follow-ups [6].

According to our understanding, most of the studies related to this outbreak identify the epidemiology and clinical characteristics of infected patients [7], the genomic classification of the virus [8], and trials for global health governance [9]. There are some COVID-19 Cohorts in the literature, but they are either retrospective or in short duration (less than three months) [10–12]. However, to the best of our knowledge, there is no study examining the changing status of this virus and its psychological impact on the infected patients in the Middle East. Although the epidemic is still ongoing, initial lessons from its spread can help inform public health officials and medical practitioners in efforts to combat its progression. Accordingly, long-term prospective Cohorts are valuable studies in this pandemic.

Iran is one of the countries with a high prevalence of COVID-19. It has been revealed that half of the Iranians have limited health literacy, which is more common in exposed groups, such as unemployed people, homemakers, and older people [13]. Isfahan, the largest city in central Iran, with about 3000 positive corona cases, is among the three top Iranian cities with a high outbreak (Fig 1). For the improvement of future preparedness plans, as well as providing a critical assessment of the resources and actionable items for stopping COVID-19 spread, utilizing lessons learned from the coronavirus outbreaks in hot zones could be helpful.

In this article, we present an effort to introduce an open-cohort from Isfahan, Khorshid COVID Cohort (KCC) study, to compile and analyze epidemiological outbreak information between COVID-19 infected patients. The objectives of our study are to provide a longitudinal overview of the patients' condition and to identify different related risk factors. This longitudinal study aimed to analyze the following signs and symptoms

findings in patients with COVID-19 pneumonia for temporal changes and also to establish the incidence of psychological disorders and related prevalent symptoms after discharge from the hospital.

It is the first study where the temporal progression between infected patients in the Middle East is explored, to the best of our knowledge. Our research data are looked-for developing evidence-driven policies to reduce the adverse effects of the increased outbreak and psychological impacts during this pandemic. It may help government agencies and policy health makers in protecting the psychological wellbeing of the society in the face of the COVID-19 outbreak in Iran and different parts of the world.

Fig 1. The prevalence of COVID-19 in different Iran provinces, including Isfahan, located in central Iran.

Materials and methods

Study population

In this prospective hospital-based surveillance study, patients who were admitted for COVID-19 from February 2020 in the Khorshid Hospital in Isfahan were recruited. Khorshid is the referral hospital for COVID-19 adults in Isfahan (Fig 2). About fifty percent of the entire CVOID-19 population from Isfahan refers to this hospital.

In this study, we diagnosed the COVID-19 patients base on the Chinese COVID-19 diagnosis and treatment guidelines, in addition to the WHO provisional advice [14]. Then, in case of a positive polymerase chain reaction (PCR) or compatible Chest computed High-resolution CT (HRCT) scan with COVID-19, the patients were recruited in this study. The ethics committee of the Isfahan University of Medical Sciences (IUMS) and the other national authorities approved the study (IR.MUI.MED.REC.1399.029). The experimental protocol was also conformed to the Declaration of Helsinki. Also, the entire subjects gave informed consent to the experimental procedure. The informed consent was given by the first relative family of patients with severe conditions. This Cohort has two phases. The first phase is on the admission information on hospitalized patients until discharge or death, while the second phase is related to the patients who were discharged from the hospital for future symptoms or social factors. Six-hundred patients were enrolled in the first phase, while four-hundred ninety patients with complete information were analyzed in this paper.

Fig 2. The scheme of the Khorshid COVID Cohort (KCC) study.

Baseline information collection

We obtained the information related to demographic, socioeconomic status (SES), medical history, underlying chronic diseases, chest computed tomographic (CT) scans, signs, symptoms, laboratory findings, treatment (including oxygen support, antibiotics, antiviral therapy, corticosteroid therapy) during the hospital admission, and outcome data

from patients medical records by Table 1 checklist. The body temperatures of the patients were taken at least four times a day. The detection of nucleic acid from the SARS-CoV-2 in upper respiratory specimens was qualitatively assessed using the PCR test. The PCR was performed once for admission.

Table 1. **Checklist of following patients who admitted to the hospital.**

Name:		Family:		
Sex: Male ☐	Female ☐			
Date of Birth:				
The number of family members:				
Occupation: Employed ☐	Unemployed ☐			
Height:		Weight:		
Education: Illiterate ☐	College ☐	Diploma ☐	Graduated ☐	
Smoking status: Yes ☐	No ☐			
Tobacco usage: Yes ☐	No ☐			
Residence Address:	Postal Code:			
Quarantine status before admission: Yes ☐	No ☐			
First Symptoms				
Sneeze ☐	Runny Nose ☐	Dry Cough ☐	Phlegm Cough ☐	Headache ☐
Body Pain ☐	Abdominal pain ☐	Nausea ☐	Vomiting ☐	Diarrhea ☐
Chest Pain ☐	Fatigue ☐	Shortness of Breath ☐	Fever ☐	
Duration Of having Symptoms (Days):				
Same symptoms In Family: Yes ☐	No ☐			
Travel History:	Where (country/City):	When (Date):		
Have you had an influenza vaccine since September? Yes ☐	No ☐			

Risk Factors
Patients with Immunodeficiency
Taking corticosteroids or other immunosuppressive drugs ☐ Malignancies ☐ Organ transplant ☐ HIV ☐ Chemotherapy History ☐
Patients with Underlying Disease
CVD ☐ Hypertension ☐ Respiratory Disease ☐ Diabetes ☐
COPD ☐ CKD ☐ Dialysis history ☐
Vital Symptoms: BP ☐ T ☐ PR ☐ RR ☐ O_2Sat ☐
Laboratory Findings: Drug Hx: CRP: Hb: WBC: LYM: PMN: PLT: CXR: CT scan Results:
Treatment Strategy
Outpatients Treatment:
Inpatients Treatment:
Suggested Treatment:

Laboratory findings

Pharyngeal swab samples were collected for the COVID-19 test on arrangement. Blood samples were collected from each participant, and routine blood test, including

Lymphocyte count (LYM), Platelet, Neutrophil (NEU), and White blood cell (WBC) counts, Na, K, BUN, CR, Ca, P and Mg were performed on the blood samples. Furthermore, blood biochemistry parameters such as C-reactive protein (CRP), Aspartate aminotransferase (AST), Alkaline phosphatase (ALP), Alanine aminotransferase (ALT), Urea, as well as lactate dehydrogenase (LDH) and Albumin were assessed using HITACHI 7600-020 automated biochemistry analyzer. Other requested parameters on admission included troponin and EKG.

Imaging protocol

We acquired the entire chest CT images using a 64-slice Philips scanner, with low-dose protocol, between patients in the supine position, without the injection of contrast, and at full inspiration. The images were evaluated by two radiologists with experience in thorax imaging. A senior investigator with at least ten years of experience at interpreting chest CT images resolved any disagreement. The following characteristics were recorded for each CT scan: distribution (craniocaudal, and transverse), the pattern, and disease severity according to a semi-quantitative scoring system [15]. Each CT scan was sub-classified according to published RSNA guidelines to the following four groups: typical, indeterminate, atypical, and negative [16].

Discharge criteria

Patients presenting the following criteria were discharged: per evaluation of the treating physician, the clinical symptoms significantly improved (respiratory rate<20, pulse rate<100, oxygen saturation of 92% while the patient was breathing ambient air), AND the

body temperature to be returned to normal for more than two days without any antipyretic medications, AND normal swallow for the solid oral medication (whole tablets and capsules), AND passing until 14 days after the onset of symptoms for patients without suitable caring system, AND good facilities for quarantine at home [17].

Follow-up

The total follow-up time lasts for one year in our study (The 1st, 4th, 12th weeks, and the first year). The following information of the discharged patients are being recorded: clinical signs and symptoms at home, possible COVID-19 recurrence, underlying diseases in their family, psychological symptoms, sleep quality, and related problems (Table 2). Discharged patients are being followed up by telephone in the first and fourth weeks to obtain whether they had any symptoms presented in Table 2. In the 12th week and the first year, each patient attends the hospital to complete the Patient Health Questionnaire-9 (PHQ-9) and the Depression Anxiety Stress Scales (DASS-21) [18]. Moreover, clinical symptoms and the respiratory function (e.g., maximal inspiratory pressure (MIP), maximal expiratory pressure (MEP), and forced vital capacity (FVC), and forced expiratory volume one second (FEV1)) are being determined in the last two follow-ups.

Table 2. **Checklist of following patients who discharge from the hospital.**

Name:	Family:
Date of discharge	
Time of follow up First ☐ Second ☐ Third ☐ Fourth ☐	
Sex: Male ☐ Female ☐	
First Symptoms	

Sneeze ☐	Runny Nose ☐	Dry Cough ☐	Phlegm Cough ☐	Headache ☐
Body Pain ☐	Abdominal pain ☐	Nausea ☐	Vomiting ☐	Diarrhea ☐
Chest Pain ☐	Fatigue ☐	Shortness of Breath ☐	Fever ☐	
Sleep disorder	Yes ☐	NO ☐		
Decreased appetite	Yes ☐	NO ☐		
Reduce the smell	Yes ☐	NO ☐		
Weight Loss	Yes ☐	NO ☐		

We used the self-report PHQ-9 questionnaire to measure the depression severity, with the total scores labeled as the following: severe depression (15–21), moderate depression (10–14), mild depression (5–9), and no depression (0–4) [19]. Depression, Anxiety, and Stress (DASS-21), a.k.a. Mental health status was measured based on previous research [20]. Stress subscale was assessed using question numbers one, six, eight, eleven, twelve, fourteen, and eighteen. The total stress subscale score was separated into five groups: extremely severe stress (35–42), severe stress (27–34), moderate stress (19–26), mild stress (11–18), and normal (0–10). Anxiety subscale was estimated using question numbers two, four, seven, nine, fifteen, nineteen, and twenty. The anxiety subscale score was also divided into five groups: extremely severe anxiety (20–42), severe anxiety (15–19), moderate anxiety (10–14), mild anxiety (7–9), and normal (0–6). The depression subscale was formed using questions three, five, ten, thirteen, sixteen, seventeen, and twenty-one. The total depression subscale score was classified as extremely severe depression (28–42), severe depression (21–27), moderate depression (13–20), mild depression (10–12), and normal (0–9). It was shown that the DASS is a reliable and valid method in measuring mental health between the Iranian population [21]. Note that the

DASS was previously used in the literature for the other version of coronavirus like SARS [22,23].

Outcomes

The initial results for the admitted patients were the following: Vital signs improvement, including SpO2, pulse and respiratory rate, blood pressure, temperature, intubation rate, death, and length of stay at the hospital. The secondary outcomes are impaired pulmonary function, later signs and symptoms, psychotic disorders, sleep disorders, and sustained end-organ failure. Moreover, The primary composite endpoint (PCEP), defined as death, the use of mechanical ventilation or admission to an intensive care unit (ICU) [24], is reported in this paper.

The research team of professionals from Khorshid Hospital and clinical faculty members of Isfahan University of medical sciences cross-checked the data. A trained team of researchers independently entered the data into a computer-based database. In a case of missing in the raw data, the coordinators were requested for clarification, to contact the corresponding clinicians. For patients who had consciousness problems on admission, we obtained data from their pre-admission information based on medical histories and through contact with their close relatives considering medical records from previous hospital visits. Further details of the KCC based on the STROBE statement were provided (S1 File).

Data analysis

First, we entered the data into the Epi-Info 3.5.3 program (https://www.cdc.gov/epiinfo/). Then, the data were analyzed using STATA v12.0 (StataCorp, College Station, TX). The patient characteristics were reported as a percentage for categorical and mean (SD) for continuous data. The endpoint in this study was death or cure from the entire COVID-19-related causes. We confirmed the endpoint by reviewing hospital medical registration, or by calling using the registered phone number. When the study period finishes, individuals alive after a follow-up time are censored. Accordingly, the subject outcome variable is death or censored after the follow-ups.

We use survival analysis to identify the connection between the patient's attributes with time from initial admission to death or the end of the follow-up after discharge are considered as covariates. The life table is used to estimate survival after the first admission, and a log-rank test is used for survival curves comparison according to different events. Time-dependent Cox regression is used to calculate the adjusted hazard rate to determine independent predictors of time to death [25]. The significance level was set to p=0.05.

Results and discussion

Descriptive statistics were calculated for socioeconomic, demographic characteristics, clinical symptoms and health service utilization, contact history, and additional health information variables (Table 3). A total of 490 first COVID-19 cases with complete information were analyzed in this manuscript, with the average age of 56.58±15.09 years (39%, female) who were admitted to the Khorshid hospital from February 2020. Eight percent of the admitted patients were transferred to the intensive care unit (ICU) (48% male). Thirty-four patients (7%) died. The top three leading causes of

admission were: fever (77%), dry cough (73%), and fatigue (69%). Sneeze (10%), runny nose (14%), and abdominal pain (17%) were the least frequent symptoms among CVOID-19 patients. The top three prevalent comorbidities with COVID-19 were hypertension (35%), diabetes (28%), and ischemic heart disease (14%).

Table 3. **Demographic, SES, comorbidities, signs and symptoms, vital symptoms, and laboratory findings of 490 patients who admitted in a COVID-19 referral hospital in Isfahan.**

Patients characteristics	**Total**	**Composite events**		**P-value**
	(N = 490)	Yes (n=90)	No (n=400)	
Age, years	56.58±15.09	61.32±16.99	55.52±14.45	<0.001
Sex (female)	191 (39%)	24 (27%)	167 (42%)	0.010
Occupation (Employed)	193 (45%)	30 (43%)	163 (46%)	0.811
Marital Status				
Single	15 (3%)	3 (3%)	12 (3%)	
Married	470 (96%)	87 (97%)	383 (96%)	0.689
Divorced or widowed	5 (1%)	0 (0%)	5 (1%)	
Number of family who infected	34 (7%)	4 (4%)	30 (8%)	0.171
Symptom duration, day	7.5±4.4	5.3±3.0	7.6±4.4	0.010
Smoking status (yes)	69 (14%)	16 (18%)	53 (13%)	0.456
Travel history to the high-risk regions (Yes)	88 (18%)	11 (12%)	77 (19%)	0.458
Quarantine before admission (Yes)	441 (90%)	78 (87%)	363 (91%)	0.014

Comorbidities (yes)				
Hypertension	171 (35%)	36 (40%)	135 (34%)	0.347
Ischemic heart disease	69 (14%)	16 (18%)	53 (13%)	0.210
Diabetes	137 (28%)	33 (37%)	104 (26%)	0.026
Immunological problems	1 (0.02%)	0 (0%)	1 (0.3%)	0.824
Acute kidney disease	15 (3%)	7 (8%)	8 (2%)	0.008
COPD	10 (2%)	5 (6%)	5 (1%)	0.151
Cancer	15 (3%)	6 (7%)	9 (2%)	0.060
Signs and symptoms (yes)				
Sneeze	49 (10%)	9 (10%)	40 (10%)	0.535
Runny nose	69 (14%)	8 (9%)	61 (15%)	0.111
Fever	377 (77%)	70 (78%)	307 (77%)	0.488
Fatigue	338 (69%)	72 (80%)	266 (67%)	0.020
Dry cough	358 (73%)	61 (68%)	297 (74%)	0.185
Headache	230 (47%)	42 (47%)	188 (47%)	0.936
Shortness of Breath	328 (67%)	63 (70%)	265 (66%)	0.371
Diarrhea	147 (30%)	22 (24%)	125 (31%)	0.499
Nausea	206 (42%)	33 (37%)	173 (43%)	0.191
Sore throat	127 (26%)	27 (30%)	100 (25%)	0.001
Vomiting	122 (25%)	22 (25%)	100 (25%)	0.556
Abdominal pain	83 (17%)	15 (17%)	68 (17%)	0.567
Vital Symptoms				
Pulse Rate, /min	95.29±17.52	96.86±19.46	95.18±17.05	0.379
Respiratory Rate, /min	22.87±10.05	24.44±9.80	22.54±10.01	0.079

SpO2, %	89.25±7.70	82.57±13.16	90.87±4.58	<0.001
Systolic blood pressure, mm Hg	133.27±19.71	134.08±22.27	132.08±18.90	0.328
Diastolic blood pressure, mmHg	82.12±29.41	79.13±17.57	82.75±13.43	0.245
Laboratory Findings				
PCR results (Positive)	335 (77%)	71 (87%)	264 (75%)	0.012
White blood cell count, $\times 10^9$ /L	6.05±3.08	7.48±4.40	5.73±2.59	<0.001
Neutrophil count, $\times 10^9$ /L	7.32±1.12	8.01±1.04	7.16±1.01	<0.001
Lymphocyte count, $\times 10^9$ /L	2.09±0.98	1.49±0.91	2.23±0.94	<0.001
Platelet count, $\times 10^9$ /L	190.35±72.51	178.13±65.07	193.18±73.90	0.051
Hemoglobin, g/dL	13.28±1.78	12.79±2.08	13.40±1.68	0.001
LDH, U/L	616.77±314.22	828.94±426.67	544.67±226.25	<0.001
AST, U/L	46.68±49.05	62.60±61.11	49.95±45.04	<0.001
ALT, U/L	32.50±32.33	44.07±54.49	29.76±23.59	0.002
ALP, U/L	168.18±96.84	195.83±181.24	162.46±60.31	0.001
Na, meq/L	134.75±3.48	134.13±4.27	134.89±3.26	0.040
Ca, mg/dL	8.55±0.73	8.33±0.95	8.60±0.67	0.001
P, mg/dL	2.94±0.76	3.22±1.10	2.88±0.65	<0.001
Mg, mg/dL	1.93±0.25	1.95±0.24	1.93±0.25	0.500
BUN, mg/dL	19.49±12.96	29.91±21.09	17.07±8.57	0.001
Cr, mg/dL	1.19±0.96	1.83±1.73	1.04±0.58	<0.001

Among 490 COVID-19 patients, 90 patients had positive PCEP. The following characteristics were not significantly different in PCEP positive and negative groups: BMI, occupation, marital status, number of infected family members, smoking status, and travel history to the high-risk regions. However, the distribution of age ($p<0.001$), sex ($p=0.010$), symptom duration ($p=0.010$), and quarantine before admission ($p=0.0140$) were significantly different in PCEP positive and negative groups. Having analyzed the comorbidities in PCEP positive and negative groups, although hypertension, Ischemic heart disease, Immunological problems, COPD, and cancer were not significant, diabetes ($p=0.026$), and acute kidney disease ($p=0.008$) were significant.

Among signs and vital symptoms, only SpO2 ($p<0.001$), fatigue ($p=0.020$), and Sore throat ($p=0.001$), and were significantly different in both groups. However, except for Mg ($p=0.500$), and platelet count ($p=0.051$), other laboratory findings were significant in the analyzed groups. Notably, elevated white blood cells ($p<0.001$), and neutrophil counts ($p<0.001$), BUN ($p=0.001$), LDH ($p<0.001$), AST ($p<0.001$), ALT ($p=0.002$), ALP ($p=0.001$), and Cr ($p<0.001$) were seen in PCEP positive groups compared with the negative groups. However, the platelet counts decreased in the PCEP group, but it was not significant ($p=0.051$). Moreover, the lymphocyte counts significantly decreased in the PCEP positive class ($p<0.001$).

The median time from admission to discharge was 5.0 days (interquartile range 3.0-8.0). The transmission route was by a history of exposure to the epidemic area (16%) or close contact with family members (25%), among which 10% of patients had both exposures. The average symptom duration was 7.5 days. A significant reduction of this time was observed in PCEP positive group respect to the negative group ($p=0.010$).

Representative samples of the COVID-19 patients were provided at https://figshare.com/s/ef91187fb69a051b8396 (50 subjects with negative PCEP and 10 subjects with positive PCEP).

This Cohort aims to identify the problems presented in COVID-19 patients from the first-time admission until death or one year after discharge. It is the first study in which COVID-19 patients are followed up to identify trends in signs and symptoms in an outbreak hot zone in the Middle East, to the best of our knowledge. The results of the first one-hundred patients were presented. It is required to perform thorough research on the novel, appearing in human infectious coronaviruses. It is then possible to explain their pathogenic mechanisms route and to recognize potential medicine. When taking into account the social effects of the outbreak, it might be possible to develop useful preventive and therapeutic medicaments. Moreover, the long-term analysis of psychological distress and symptoms of mental illness of such patients after hospital discharge was taken into account in our Cohort. Such issues are fundamental, in general, in this pandemic [26].

According to our laboratory-confirmed cases, the common clinical manifestations were fever (77%), dry cough (73%), fatigue (69%), and shortness of breath (67%). The three most common clinical manifestations were consistent with the studies in China [7,24,27,28]. In laboratory examination results, less than 20% of the patients had decreased white blood cell counts. Also, the percentage of lymphocytopenia was 4%. It was in contrast with other studies that reported that most of their patients had this problem [24,29].

Previous studies demonstrated that the elderly and those with underlying disorders (i.e., cardiovascular diseases, diabetes, hypertension, and chronic obstructive pulmonary

disease) developed rapidly into ARDS, even leading to ICU admission or death [7]. Although our findings presented that the rate of death and ICU admission was 7% and 14%, a similar condition was observed. Cardiac complications, including heart failure, arrhythmia, or myocardial infarction, are common in patients with pneumonia.

It might be possible to reduce the probability of COVID-19 incidence and distress, reporting high-risk pathogens, social effects of this disease, which can help the health policymakers for leading reasonable policies when using our cohort results. Most people show mild symptoms. However, it may progress to ARDS, pneumonia, and multi-organ dysfunction in older people and those with comorbidities [30]. Many patients who survive acute viral pneumonia have impaired functions and health status in the first few months of recovery. However, long-term sequelae are still mostly unknown [31]. Patients who survived an episode of ARDS may have marked dyspnea and severe respiratory physiological abnormalities. Although a one-year post-ICU follow-up study showed that survivors of A(H1N1)-associated ARDS had minor lung disabilities [32], both obstructive and restrictive deficits have been reported in patients with ARDS. The ARDS survivors often suffer prolonged myopathy limiting activities of daily living, posttraumatic stress disorder (PTSD), and increased number of deaths after apparent recovery. Such problems usually exist for more than three months. Moreover, many patients show continuous neurocognitive dysfunction for one to two years. When managing these problems supportively, the knowledge of the PTSD persistency in such patients is required [33].

The medical and public health infrastructure and the economy were affected by this new virus outbreak worldwide. Several studies have reported adverse psychological complications, including confusion, symptoms of traumatic stress, and anger in cases, who

encountered stressful situations. The long quarantine period, fear of disease, boredom, despair, inadequate food shortages, insufficient information, stigma, and financial loss are known as stressors in the COVID-19 epidemic [34,35]. Along with this, the primary purpose of this study is to identify psychological problems among discharged patients for one year.

It takes time to see how the virus affects our lives here in Iran and other parts of the world. It is also possible to have similar future outbreaks. Besides limiting this outbreak, preventive programs must be planned for such problems. It is of great importance when considering the warning by the WHO chief as "the virus will be with us for a long time."

It must be mentioned that self-reporting used for the first two follow-ups has some limitations in comparison with face-to-face interviews for the second and third follow-ups. Also, psychological studies do not necessarily probe psychological services efficacy. Thus, dynamic observations and more follow-ups are necessary. The larger sample size is also required for result verification, which is available during the Cohort. Apart from such limitations, it is possible to perform a risk assessment and to use medical data mining for diagnosis and prognosis to identify complex interactions.

Conclusions

The COVID-19 outbreak has become a clinical danger to the general population and healthcare workers worldwide. However, knowledge about the trend of this novel virus, which leads to different symptoms and outcomes, remains limited. The practical option of different treatment, underlying disease, clinical findings, and different symptoms or signs

on the disease prognosis is under evaluation and development. What we can do now is to design a cohort to follow patients to identify the underlying trend based on different outcomes and their risk assessment. It may assist healthcare policymakers and government agencies, and in the managing of health, and resources following this pandemic.

Acknowledgments

We would like to acknowledge the Khorshid hospital nurses and interns for this study, who recruited patients and collected follow-up data. Most importantly, we would like to acknowledge all the patients who consented to take part in this study.

References

1. Liu S, Yang L, Zhang C, Xiang Y-T, Liu Z, Hu S, et al. Online mental health services in China during the COVID-19 outbreak. Lancet Psychiatry. 2020;7: e17–e18. doi:10.1016/S2215-0366(20)30077-8

2. Jiang S, Shi Z-L. The First Disease X is Caused by a Highly Transmissible Acute Respiratory Syndrome Coronavirus. Virol Sin. 2020. doi:10.1007/s12250-020-00206-5

3. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020. doi:10.1016/S1473-3099(20)30120-1

4. MacIntyre R. The risk of selective investment in downstream pandemic planning. Global Biosecurity. 2019. p. 85. doi:10.31646/gbio.36

5. Wynants L, Van Calster B, Bonten MMJ, Collins GS, Debray TPA, De Vos M, et al. Prediction models for diagnosis and prognosis of covid-19 infection: systematic review and critical appraisal. BMJ. 2020;369: m1328. doi:10.1136/bmj.m1328

6. Wang Y, Dong C, Hu Y, Li C, Ren Q, Zhang X, et al. Temporal Changes of CT Findings in 90 Patients with COVID-19 Pneumonia: A Longitudinal Study. Radiology. 2020; 200843. doi:10.1148/radiol.2020200843

7. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395: 497–506. doi:10.1016/S0140-6736(20)30183-5

8. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395: 565–574. doi:10.1016/S0140-6736(20)30251-8

9. Rubin GJ, Wessely S. The psychological effects of quarantining a city. BMJ. 2020;368: m313. doi:10.1136/bmj.m313

10. Du R-H, Liang L-R, Yang C-Q, Wang W, Cao T-Z, Li M, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur Respir J. 2020;55. doi:10.1183/13993003.00524-2020

11. Bi Q, Wu Y, Mei S, Ye C, Zou X, Zhang Z, et al. Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. Lancet Infect Dis. 2020. doi:10.1016/S1473-3099(20)30287-5

12. Khairat S, Meng C, Xu Y, Edson B, Gianforcaro R. Interpreting COVID-19 and Virtual Care Trends: Cohort Study. JMIR Public Health Surveill. 2020;6: e18811. doi:10.2196/18811

13. Montazeri A, Tavousi M, Rakhshani F, Azin SA, Jahangiri K, Ebadi M, et al. Health Literacy for Iranian Adults (HELIA): development and psychometric properties. Payesh (Health

Monitor). 2014;13: 589–599. Available: http://payeshjournal.ir/browse.php?a_id=279&sid=1&slc_lang=en

14. Jernigan DB, CDC COVID-19 Response Team. Update: Public Health Response to the Coronavirus Disease 2019 Outbreak - United States, February 24, 2020. MMWR Morb Mortal Wkly Rep. 2020;69: 216–219. doi:10.15585/mmwr.mm6908e1

15. Pan F, Ye T, Sun P, Gui S, Liang B, Li L, et al. Time Course of Lung Changes On Chest CT During Recovery From 2019 Novel Coronavirus (COVID-19) Pneumonia. Radiology. 2020; 200370. doi:10.1148/radiol.2020200370

16. Simpson S, Kay FU, Abbara S, Bhalla S, Chung JH, Chung M, et al. Radiological Society of North America Expert Consensus Statement on Reporting Chest CT Findings Related to COVID-19. Endorsed by the Society of Thoracic Radiology, the American College of Radiology, and RSNA. Radiology: Cardiothoracic Imaging. 2020;2: e200152. doi:10.1148/ryct.2020200152

17. Guidance for discharge and ending isolation in the context of widespread community transmission of COVID-19 – first update. In: European Centre for Disease Prevention and Control [Internet]. 8 Apr 2020 [cited 7 May 2020]. Available: https://www.ecdc.europa.eu/en/publications-data/covid-19-guidance-discharge-and-ending-isolation

18. Ell K, Unützer J, Aranda M, Sanchez K, Lee P-J. Routine PHQ-9 depression screening in home health care: depression, prevalence, clinical and treatment characteristics and screening implementation. Home Health Care Serv Q. 2005;24: 1–19. doi:10.1300/J027v24n04_01

19. Kocalevent R-D, Hinz A, Brähler E. Standardization of the depression screener patient health questionnaire (PHQ-9) in the general population. Gen Hosp Psychiatry. 2013;35: 551–555. doi:10.1016/j.genhosppsych.2013.04.006

20. Le TA, Le MQT, Dang AD, Dang AK, Nguyen CT, Pham HQ, et al. Multi-level predictors of

psychological problems among methadone maintenance treatment patients in difference types of settings in Vietnam. Subst Abuse Treat Prev Policy. 2019;14: 39. doi:10.1186/s13011-019-0223-4

21. Sahebi A, Asghari MJ, Salari RS. Validation of Depression Anxiety and Stress Scale (DASS-21) for an Iranian Population. Scientific Journal Management System. 2005;1: 36–54. Available: http://jip.azad.ac.ir/article_512443.html

22. Sim K, Huak Chan Y, Chong PN, Chua HC, Wen Soon S. Psychosocial and coping responses within the community health care setting towards a national outbreak of an infectious disease. J Psychosom Res. 2010;68: 195–202. doi:10.1016/j.jpsychores.2009.04.004

23. Leung GM, Lam T-H, Ho L-M, Ho S-Y, Chan BHY, Wong IOL, et al. The impact of community psychological responses on outbreak control for severe acute respiratory syndrome in Hong Kong. J Epidemiol Community Health. 2003;57: 857–863. doi:10.1136/jech.57.11.857

24. Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020. doi:10.1056/NEJMoa2002032

25. Moore DF. Applied Survival Analysis Using R. Springer International Publishing; 2016. Available: https://play.google.com/store/books/details?id=7bRjjwEACAAJ

26. Rajkumar RP. COVID-19 and mental health: A review of the existing literature. Asian J Psychiatr. 2020;52: 102066. doi:10.1016/j.ajp.2020.102066

27. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020. doi:10.1001/jama.2020.1585

28. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a

descriptive study. Lancet. 2020;395: 507–513. doi:10.1016/S0140-6736(20)30211-7

29. Liu K, Fang Y-Y, Deng Y, Liu W, Wang M-F, Ma J-P, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J . 2020. doi:10.1097/CM9.0000000000000744

30. Singhal T. A Review of Coronavirus Disease-2019 (COVID-19). Indian J Pediatr. 2020;87: 281–286. doi:10.1007/s12098-020-03263-6

31. Chan KS, Zheng JP, Mok YW, Li YM, Liu YN, Chu CM, et al. SARS: prognosis, outcome and sequelae. Respirology. 2003;8 Suppl: S36–40. doi:10.1046/j.1440-1843.2003.00522.x

32. Luyt C-E, Combes A, Becquemin M-H, Beigelman-Aubry C, Hatem S, Brun A-L, et al. Long-term outcomes of pandemic 2009 influenza A(H1N1)-associated severe ARDS. Chest. 2012;142: 583–592. doi:10.1378/chest.11-2196

33. Spencer-Segal JL, Hyzy RC, Iwashyna TJ, Standiford TJ. Psychiatric Symptoms in Survivors of Acute Respiratory Distress Syndrome. Effects of Age, Sex, and Immune Modulation. Ann Am Thorac Soc. 2017;14: 960–967. doi:10.1513/AnnalsATS.201606-468OC

34. Yang Y, Peng F, Wang R, Guan K, Jiang T, Xu G, et al. The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China. J Autoimmun. 2020; 102434. doi:10.1016/j.jaut.2020.102434

35. Brooks SK, Webster RK, Smith LE, Woodland L, Wessely S, Greenberg N, et al. The psychological impact of quarantine and how to reduce it: rapid review of the evidence. Lancet. 2020;395: 912–920. doi:10.1016/S0140-6736(20)30460-8

Supporting information

S1 File. The specification of the KCC based on STROBE Statement.


COVID-19 Prevalence Distribution in IRAN
27 March 2020
Isfahan
50-99
100-199
200-499
500-999
1000-1999
2000-4999
> 5000
Number of patients


Death
Referral Hospital
Admission
Follow-Up
End Of study
Discharge
1-Year Follow-Up
1st week
4th week
12th week
1-Year